medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (1)

Positron emission tomography combined with computed tomography for the staging of lymphomas

Fundora STA, Hernández RLH, Chávez Pérez-Terán MD

Language: Spanish
References: 23
Page: 1-14
PDF size: 346.79 Kb.


ABSTRACT

Introduction: Imaging studies are essential for staging of lymphomas. The usage of functional imaging provided by positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography has fundamentally changed the concept of staging and re-staging of lymphomas. It constitutes a diagnostic test that has gained universal acceptance, especially after the publication and adoption of the Lugano guidelines.
Objective: To analyze the importance of the images provided by positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography in current staging of lymphomas.
Methods: A bibliographic review was carried out, in Spanish and in English, within the last decade. We used the search engines of Pubmed, Google, and SciELO. The information was collected and organized by chronologically following the origin of the innovations that facilitate the staging of lymphomas. Information analysis and synthesis: An analysis is carried out from the introduction of computed tomography, positron emission tomography, and the combination of both, to their application in the study of lymphomas. We described the evolution of lymphoma classification systems and the usefulness of positron emission tomography with 18F-2-deoxy-2-fluoro-D-glucose combined with computed tomography for the staging of lymphomas.
Conclusions: At the present time, it is of great importance for a patient with lymphoma needing 18F-2-deoxy-2-fluoro-D-glucose to receive optimal management of his or her condition, including initial staging with positron emission tomography combined with computed tomography. This will allow to make the initial staging of the patient more precise, to optimize his or her treatment and evaluation of the implemented therapy, as well as to obtain a better prognosis, avoiding invasive studies.


REFERENCES

  1. Bosch E. Sir Godfrey Newbold Hounsfield y la tomografía computada, su contribución a la medicina moderna. Rev Chil Radiol. 2004;10(4):183-5.

  2. Beckmann EC. CT scanning the early days. Br J Radiol. 2006;79:5-8. doi: 10.1259/bjr/29444122

  3. Lovera C. Manual de Medicina Nuclear. 2015 [acceso 11/11/2018]. Disponible en: http://www.medicinanuclear.cl/pet_indice-2.htm

  4. Ruiz JA. Tomografía por emisión de positrones (PET): evolución y futuro. Radiobiología 2007 [acceso 11/11/2018];7:148-56. Disponible en: http://www-rayos.medicina.uma.es/rmf/radiobiologia/revista/numeros/RB7(2007)148-156.pdf

  5. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-79.

  6. Martí-Climent JM, García P, Serra JF, Boán JA, Richter JA. Tomografía por emisión de positrones con un equipo PET/TAC. Rev Esp Med Nucl. 2005;24(1):60-79. doi: 10.1157/13070362

  7. Press OW, Lichtman MA. General considerations for Lymphomas: Epidemiology, Etiology, Heterogeneity, Primary Extranodal Disease. En: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al (editores). Williams Hematology 9th ed. New York: McGraw-Hill Education; 2016. p. 1569-86.

  8. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31:1860-1.

  9. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-66. doi: 10.1200/JCO.1989.7.11.1630

  10. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:2454-60. doi: 10.1200/JCO.1999.17.4.1244

  11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Spetch L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. doi: 10.1200/JCO.2006.09.2403

  12. Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1004-27. doi: 10.1007/s00259-013-2686-2

  13. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Martin Hutchings M, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048-58. doi: 10.1200/JCO.2013.53.5229

  14. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca, E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014;32:3059-68. doi: 10.1200/JCO.2013.54.8800

  15. Kostakoglu L. Guest editorial. Semin Nucl Med. 2018;48(1):1-3.

  16. El-Galaly TC, Gormsen LC, Hutchings M. PET/CT for Staging; Past, Present, and Future. Semin Nucl Med. 2018;48(1):4-16.

  17. Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz F, Borrego-Dorado I, Ruiz M, Acevedo I. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol. 2015;33:151-68. doi: 10.1002/hon.2181

  18. Albano D, Bosio G, Giubbini R, Bertagna F. 18F-FDG PET/CT and extragastric MALT lymphoma: Role of Ki-67 score and plasmacytic differentiation. Leuk Lymphoma. 2017;58(10):2328-34. doi: 10.1080/10428194.2017.1298754

  19. Novelli S, Briones J, Flotats A, Sierra J. PET/CT assessment of follicular lymphoma and high grade B cell lymphoma-Good correlation with clinical and histological features at diagnosis. Adv Clin Exp Med. 2015;24:325-30. doi: 10.17219/acem/31804

  20. Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531-8. doi: 10.1182/blood-2015-11-679407.

  21. Cerci JJ, Bogoni M, Buccheri V, Sa de Camargo EC, Bruno TM, Baiochi O, et al. Fluorodeoxy glucosa – positron emission tomography staging can replace bone marrow biopsy in Hodgkin’s lymphoma. Results from the Brasilian Hodgkin’s Lymphoma Study Group. Hematol Transfus Cell Ther. 2018;40(3):245-9.

  22. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W et a. FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-54. doi: 10.1007/s00259-014-2961-x

  23. Kostakoglu L, Chauvie S. Metabolic Tumor Volume Metrics in Lymphoma. Semin Nucl Med. 2018;48(1):50-66.




2020     |     www.medigraphic.com